LM-2417 + niraparib

**LM-2417 + niraparib** is an investigational combination therapy being evaluated for advanced solid tumors. LM-2417 is an experimental agent (details on its specific molecular class and mechanism are not publicly available), developed by LaNova Medicines, and is currently being studied both as monotherapy and in combination with established anti-cancer agents, including niraparib. **Niraparib** is an orally administered small molecule PARP (poly ADP-ribose polymerase) inhibitor, approved for certain gynecological cancers, which blocks enzymes involved in DNA repair, leading to increased DNA damage and cancer cell death, especially in tumors with defective homologous recombination repair mechanisms, such as those with BRCA mutations. The combination is designed for potential synergistic effects in treating advanced solid tumors[1][7][2][5][8].

Other names

LM-2417LM2417LM 2417niraparib